Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Current Deferred Revenue (2016 - 2025)

Capricor Therapeutics has reported Current Deferred Revenue over the past 8 years, most recently at $12.0 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $12.0 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $12.0 million (changed 0.0% YoY), and the annual figure for FY2025 was $12.0 million, changed 0.0%.
  • Current Deferred Revenue for Q4 2025 was $12.0 million at Capricor Therapeutics, roughly flat from $12.0 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for CAPR hit a ceiling of $40.0 million in Q1 2022 and a floor of $12.0 million in Q4 2024.
  • Median Current Deferred Revenue over the past 4 years was $16.9 million (2022), compared with a mean of $19.4 million.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 86.16% in 2023 and later plummeted 50.56% in 2024.
  • Capricor Therapeutics' Current Deferred Revenue stood at $18.0 million in 2022, then surged by 34.98% to $24.3 million in 2023, then tumbled by 50.56% to $12.0 million in 2024, then changed by 0.0% to $12.0 million in 2025.
  • The last three reported values for Current Deferred Revenue were $12.0 million (Q4 2025), $12.0 million (Q3 2025), and $12.0 million (Q2 2025) per Business Quant data.